Charles Bhatt

Charles Bhatt specializes in DNMT inhibitor-based epigenetic therapy at Johns Hopkins, with a focus on cancer epigenome reprogramming as a therapeutic strategy. His research has investigated how low-dose DNMT inhibitors can restore tumor suppressor gene expression and enhance cancer cell immunogenicity through demethylation of transposable elements. He has contributed to clinical trials combining azacitidine and decitabine with immunotherapy in solid tumors and hematologic malignancies. His work illuminates the mechanistic basis for epigenetic-immunotherapy synergy.